Comparative Pharmacology
Head-to-head clinical analysis: KEVZARA versus SARCLISA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEVZARA versus SARCLISA.
KEVZARA vs SARCLISA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Interleukin-6 (IL-6) receptor antagonist; sarilumab binds specifically to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling through gp130 and STAT3.
Isatuximab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, inducing apoptosis through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). It also inhibits CD38 enzymatic activity.
200 mg subcutaneously once weekly.
10 mg/kg intravenously weekly for the first 8 weeks, then every 2 weeks thereafter until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life ~21-22 days, supporting subcutaneous dosing every 2 weeks.
Terminal elimination half-life: 9-14 days (approx. 4 weeks to reach steady state in multiple dosing).
Primarily eliminated via reticuloendothelial system catabolism. No significant renal or biliary excretion; <1% excreted unchanged in urine or feces.
Renal: ~25% unchanged; Biliary/fecal: minor, primarily metabolized via liver, with metabolites excreted in bile/feces.
Category C
Category C
Monoclonal Antibody, IL-6 Receptor Antagonist
Monoclonal Antibody, Antineoplastic